Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2 2024. Revenue increased 68% to $34.9 million, driven by a 92% increase in Light Adjustable Lens (LAL) sales and 32% growth in Light Delivery Device (LDD) revenue. The company sold 24,214 LALs and 78 LDDs, expanding its installed base to 810 LDDs. Gross profit rose 102% to $24.3 million, with a margin of 69.5%. Despite higher operating expenses, the net loss narrowed to $(6.1) million, or $(0.16) per share. RxSight raised its 2024 guidance, projecting revenue of $139-140 million and operating expenses of $135-136 million. The company's cash position strengthened to $233.3 million, bolstered by a recent public offering.
RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, has announced it will release its second quarter 2024 financial results on August 5, 2024, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results. Interested parties can register for the call, with a recommendation to join ten minutes early to ensure proper setup. A dial-in option will be available, and the call will be live-streamed and archived for one year on the company's investor relations website.
RxSight, a company specializing in ophthalmic medical devices, announced its participation in the Truist Securities Medtech Conference. The event will include a fireside chat with RxSight's management on June 18, 2024, at 12:05 p.m. Pacific Time / 3:05 p.m. Eastern Time. A live and archived webcast of the presentation will be available on their investor relations website.
RxSight, an ophthalmic medical device company, has successfully closed its public offering of 2,053,571 shares of common stock at $56.00 per share. This includes the full exercise of underwriters' option to purchase an additional 267,857 shares, generating gross proceeds of $115 million. The offering was managed by BofA Securities, J.P. Morgan, and BTIG, with BofA Securities acting as the lead bookrunning manager. The automatic shelf registration statement and the final prospectus supplement were filed with the SEC on May 8, 2024. The proceeds are expected to support RxSight’s ongoing business activities and growth strategies.
RxSight, Inc., a medical device company specializing in vision care post cataract surgery, announced the pricing of its public offering of common stock. The company plans to sell 1,785,714 shares at $56.00 per share, expecting gross proceeds of approximately $100.0 million. The offering is set to close around May 13, 2024, with plans to utilize the funds for commercial expansion, product development, research, and general corporate purposes.
RxSight, Inc. announced a proposed public offering of $100 million of its common stock, with an additional 15% option for underwriters. The company plans to use the proceeds for commercial expansion, product development, research, and working capital. BofA Securities, J.P. Morgan, and BTIG are involved in the offering. An automatic shelf registration statement was filed with the SEC. The offering will be made through a prospectus supplement and accompanying prospectus.
RxSight, Inc. reported strong first quarter 2024 financial results, with a revenue of $29.5 million, a 69% increase compared to the first quarter of 2023. The company sold 20,218 Light Adjustable Lenses (LAL) and 66 Light Delivery Devices (LDD), showing significant growth in procedure volume and unit sales. Gross profit increased to $20.7 million, operating expenses rose to $31.4 million, and the company reported a net loss of $(9.1) million. However, adjusted net loss improved to $(4.4) million. Cash, cash equivalents, and short-term investments were $125.4 million as of March 31, 2024. RxSight raised its 2024 revenue guidance to $132.0 million to $137.0 million, gross margin guidance to 68% to 70%, and operating expense guidance to $126.0 million to $130.0 million.
RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.
Summary not available.
Summary not available.